Relationship Graph Explorer
Follow the connections
Every herb, ingredient, formula, gene target, and disease — connected through real research. Search, pick a subject, and navigate the graph in any direction.
🌿
Herb
6,826
→
⚗️
Ingredient
45,885
→
🧬
Gene Target
15,695
→
🏥
Disease
30,467
→
🧪
Evidence
23,241
trials · metas · refs
Plus 6,743 TCM formulas connecting herbs together
🏥 Disease / Health Topic
Ovarian Neoplasms
10
Clinical Trials
0
Meta-Analyses
0
PubMed References
📋 Sample Trials
NCT00001272
A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients
Completed · Phase 1
NCT01015118
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Completed · Phase 3
NCT00191646
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Completed · Phase 3
📊 Sample Meta-Analyses
None linked yet.
📚 Sample References
None linked yet.
🏥 All Disease / Health Topic data fields for Ovarian Neoplasms
🏥 Names
Disease Name
Ovarian Neoplasms
Topic Type
disease
🔍 Raw view — every non-empty column on this row (14 fields)
name
Ovarian Neoplasms
topic type
disease
tcmsp disease id
598
🌿 Related Herbs
1 · contains this compound⚗️ Related Ingredients
4 · compounds in this herb🧬 Gene / Protein Targets
2 · genes implicated in this diseaseCytochrome P450 1A2
Glutathione S-transferase P
📋 Clinical Trials
10 · subject of clinical studyNCT00001272 A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Sti
→ Ovarian Neoplasms
NCT01015118 LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel an
→ Ovarian Neoplasms|Peritoneal Neoplasms
NCT00191646 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That
→ Genital Neoplasms, Female|Fallopian Tube Neoplasms
NCT01462890 Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standar
→ Genital Diseases, Female|Ovarian Diseases|Ovarian
NCT01616303 A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemothera
→ Ovarian Neoplasms
NCT02429687 TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
→ Ovarian Germ Cell Cancer|Ovarian Neoplasms|Ovarian
NCT02429700 TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
→ Ovarian Sex Cord Stromal Tumor|Ovarian Neoplasms|O
NCT03648489 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube o
→ Ovarian Cancer|Ovarian Neoplasms|Ovarian Carcinosa
NCT04498117 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovari
→ Carcinoma, Ovarian Epithelial|Ovarian Neoplasms|Ov
NCT05185947 Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Perit
→ Gynecologic Cancer|Gynecologic Neoplasms|Peritonea
How to read these connections
Each box lists records connected to the one you are viewing, and says how the connection was made. A connection shows that two records are related in the source data. It does not show that something works, is safe or should be used, and a record with many connections is not necessarily better studied or more effective.
- Study records (trials, systematic reviews, publications): the study names this subject. Registered or ongoing studies have no results here, and animal or cell research does not show an effect in people.
- Source-database links (for example herb and compound, compound and gene target): taken from the imported databases and not independently checked by us.
- Name matches (for example formula and herb, or a condition named in a study): found by matching names, so they can be wrong. Treat them as leads, not findings.